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Circulating cytokines in Norwegian patients with psoriatic
arthritis determined by a multiplex cytokine array system
P. Szodoray*, P. Alex1,*, C. M. Chappell-Woodward2,*, T. M. Madland3, N. Knowlton1,
I. Dozmorov1, M. Zeher4, J. N. Jarvis5, B. Nakken6, J. G. Brun3 and M. Centola1
Objectives. Serum cytokines play an important role in the pathogenesis of psoriatic arthritis (PsA) by initiating and
perpetuating various cellular and humoral autoimmune processes. The aim of this study was to describe a broad spectrum of
T- and B-cell cytokines, growth factors and chemokines in patients with PsA and healthy individuals.
Methods. A novel protein array system, denoted as multiplex cytokine assay was utilized to measure simultaneously the levels
of 23 circulating cytokines of patients with PsA and healthy individuals. Additionally, correlational clustering and discriminant
function analysis (DFA), two multivariate, supervised analysis methods were employed to identify a subset of biomarkers in
order to describe potential functional inter-relationships among these pathological cytokines and identify biomarkers with
prognostic and diagnostic utility.
Results. Univariate analysis demonstrated that serum levels of a complex set of immune and inflammatory modulating
cytokines are significantly up-regulated in patients with PsA relative to unaffected controls including interleukin (IL)-10, IL-13,
interferen (IFN)-, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor
[CCL3 macrophage inflammatory protein (MIP)-1], CCL4 (MIP-1) and CCL11 (Eotaxin), while granulocyte-colony
stimulating factor was significantly reduced in PsA patients. Correlational clustering was able to discriminate among, and
hence subclassify, patients with varying levels of disease activity, which may prove useful in guiding therapy in these apparently
phenotypically distinct disease subsets. DFA identified EGF, IFN-, VEGF, CCL3 (MIP-1) and IL-12p40 as analytes with
the strongest discriminatory power among various PsA patients and controls.
Conclusions. Our findings suggest that these factors modulate PsA pathology and the articular involvement in a synergistic
manner. Identifying factors could be used in the development of clinical diagnostic tests, which are valuable to guide evidence-
based diagnosis and disease management of PsA.
KEY WORDS: Psoriatic arthritis, Circulating cytokines, Hierarchical clustering, Discriminant function analysis, Disease activity, Multiplex
cytokine array system.
Introduction
Arthritides, associated with psoriasis is a heterogeneous disease
entity consisting of monoarticular, oligoarticular and/or
polyarticular type of peripheral joint involvement. The disease is
also characterized by erosive manifestations, bony periosteal
reaction, exuberant proliferation at sites of enthesis and the
presence of bony ankylosis [1]. Psoriatic arthritis (PsA) has been
diagnosed in 20% of those who have psoriasis and manifests in
most patients between the ages of 20 and 50 yrs [1]. In addition to
the peripheral joint synovitis and spontaneous joint fusion,
patients present with dermatological manifestations of psoriasis,
rheumatoid factor (RF) seronegativity and human leucocyte
antigen (HLA) associations [2]. The pathological process of skin
and joint lesions in PsA is primarily mediated by autoimmune
inflammatory reaction and a pathogenic interplay of genetic and
environmental factors [3].
The prominent inflammatory lymphocytic infiltrate in the skin
dermal papillae, the joint stroma and at inflammatory enthesis
reflects a complex cytokine profile in PsA [1]. Cytokines,
as molecular mediators of the inflammatory process in PsA
including tumour necrosis factor (TNF)- [4, 5], have previously
been described as crucial factors in the pathogenesis of the
disease. Other cytokines, such as interleukin (IL)-10, IL-12, IL-13,
IL-18 and vascular endothelial growth factor (VEGF), have
also been described to have a pathogenic role in PsA [6–9]. These
studies suggest that cytokines secreted from activated T- and B-
cells and other immunocompetent cells induce
proliferation and activation of the synovial and epidermal
fibroblasts leading to clinical manifestations of arthritis
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in these patients. The importance of this class of disease
mediators is underscored by the highly efficacious action of
anti-cytokine-based biological therapies in PsA and other
inflammatory arthritides [10, 11]. Circulating cytokines therefore
reflect the activation status of ongoing inflammatory processes
and the evaluation of serum cytokines is a good indicator and
a reliable surrogate marker of disease activity in inflammatory
arthritides [12, 13].
Clinical studies of cytokine function in inflammatory arthritis
can be controversial and even contradictory. The roles of
cytokines in health and disease can be blurred due to the
complexity of cytokine mechanics, including kinetics of expres-
sion, mode of induction, regulation of receptor expression,
competition for occupancy, and synergy of action, all critical
aspects of their net effect. Moreover, there are differences in
pathological manifestations, disease severity and drug response
among patients that must be considered in cohort studies of
cytokine function to accurately define their role in health and
disease [14].
Broad-based proteomic screening methods are beginning to
reveal the rich repertoires of cytokines at play in a given form
of autoimmune diseases or inflammatory arthritides [15, 16].
Moreover, increasingly sophisticated multi-variant analyses
methods have been developed to aid in our understanding
of the complex regulatory networks of these disease mediators
[17–19].
The aim of this study was to first catalogue a broad spectrum
of lymphokines, monokines, chemokines, growth and angiogenic
factors in the periphery of PsA patients, then model putative
regulatory networks among these factors, using multivariate
biostatistical methods and clinical correlations. In doing so,
we have verified the presence of previously characterized and
identified novel cytokines up-regulated in PsA sera, mediators
with both diagnostic and mechanistic potential. We have also
characterized likely interplay among these cytokines using multi-
variate analysis methods that model network-like behaviours
among biological variables.
Materials and methods
Patients and controls
The study population consisted of 43 Norwegian patients with
PsA of polyarticular type who were recruited from the out-patient
clinic at the Department of Rheumatology, Haukeland University
Hospital, Bergen, Norway (24 females and 19 males; mean age
53.77 yrs, range 26–74) fulfilling the diagnosis of PsA according to
the criteria of Moll and Wright [20]. Also 25 age- and sex-matched
healthy controls were enrolled in the study. These controls
were healthy blood donors, without any sign of arthritis, psoriasis
or ongoing inflammation. Controls were medication-free for
at least 3 months prior to this study. To assess the present
disease activity, clinical examination of 52 joints was performed
(the EULAR 44 joint count added to DIP joints of hands).
Skin affection by psoriasis was assessed using the PASI score [21].
Before inclusion in the study, informed consent was signed
by each patient.
General laboratory and immunolaboratory assessments
included erythrocyte sedimentation rate, C-reactive protein,
white blood cell count, haemoglobin, anti-nuclear antibody
and RF. Clinical and laboratory characteristics of the patients
included in the study are summarized in Table 1.
Serum samples
Blood samples were obtained from both patients and unaffected
controls after informed consent and treated anonymously
throughout the analysis. Blood was collected in endotoxin-free
silicone-coated tubes without additive. The blood samples were
allowed to clot at room temperature for 30min before centrifuga-
tion (3000 rpm, 48C, 10min), the serum was removed and stored
at 808C until analysed.
Multiplex cytokine assay
Serum levels of cytokines and chemokines, including IL-1, IL-2,
IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-12 (p40), IL-13, IL-15,
IL-17, interferon (IFN)- and IFN-, TNF-, epidermal growth
factor (EGF), VEGF, basic fibroblast growth factor (FGF),
granulocyte-colony stimulating factor (G-CSF), granulocyte-
macrophage colony stimulating factor (GM-CSF), CCL2
[monocyte chemoattractant protein (MCP)-1]/(MCAF), CCL3
[macrophage inflammatory protein (MIP)-1], CCL4 (MIP-1)
and CCL11 (Eotaxin) were measured using a bead-based
immunofluorescence assay (Luminex Inc. Austin, TX, USA)
using multiplex cytokine reagents supplied by Biosource
International, Camarillo, CA, USA as previously described
[16, 22]. Briefly, a sandwich immunoassay-based protein array
system (Biosource International), which contains dyed micro-
spheres conjugated with a monoclonal antibody specific for a
target protein was used in this assay. Serum samples were thawed
and run in duplicates. Antibody-coupled beads were incubated
with the plasma sample (antigen) after which they were incubated
with biotinylated detection antibody before finally being incu-
bated with streptavidin–phycoerythrin. A broad sensitivity range
of standards (Biosource International), ranging between 1.95 and
32 000 pg/ml were used to help enable the quantitation of a
dynamic wide range of cytokine concentrations and provide the
greatest sensitivity. This captured bead-complexes were then
read by the Bio-Plex array reader (Bio-Rad Laboratories,
Hercules, CA), which uses Luminex fluorescent bead-based
technology (Luminex Corporation Austin, TX, USA) with a
flow-based dual laser detector with real-time digital signal
processing to facilitate the analysis of up to 100 different families
of colour-coded polystyrene beads and allow multiple measure-
ments of the sample ensuring in the effective quantification
of cytokines.
Validation of the multiplex assays was performed using
single protein ELISAs (Biosource International). Values obtained
from multiplex assay analytes were highly correlative (Spearman’s
rank correlation coefficient, 0.97 0.03) when compared with
individual ELISAs for particular cytokines.
Serum levels of 23 cytokines were compared among PsA
patients and unaffected control individuals, also among various
subsets of patients with PsA. The cytokines assayed included
modulators of several key aspects of disease pathology including
regulation of inflammation, cellular and humoral immunity,
leukocyte trafficking, cell growth and angiogenesis. To facilitate
functional interpretation of results, cytokines were sorted into
four functional groups in the graphical representations of these
analyses. This included a group denoted ‘cellular cytokines’ which
drive, albeit not exclusively, cytotoxic and anti-viral responses
(e.g. IL-1, IL-2, IL-12p40, IL-15, IL-17, TNF-, IFN-, IFN-),
‘humoral cytokines’ (e.g. IL-4, IL-5, IL-6, IL-10, IL-13),
‘growth and angiogenic factors’ (e.g. EGF, VEGF, FGF basic,
G-CSF, GM-CSF) and ‘chemokines’ [e.g. CCL2 (MCP-1),
CCL3 (MIP-1), CCL4 (MIP-1), CCL11 (Eotaxin) and
CXCL8 (IL-8)].
Statistical analysis
The concentrations of analytes in these assays were quantified
using a calibration or standard curve. A 5-parameter logistic
regression analysis was performed to regress a known serial
dilution of analyte vs median fluorescent intensity read
from a flow cytometer. The resulting equation was then used
to predict the concentration of the unknown samples [23].
418 P. Szodoray et al.
 at U
niversity of D
ebrecen, Faculty of M
edicine, Central Library on M
ay 5, 2012
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
Statistical differences in measured values were analysed using
a Mann–Whitney U-test. P-values <0.05 were considered
statistically significant. All P-values reported are nominal due to
the exploratory nature of this analysis. Matlab R13 (Natick, MA,
USA) and Statistica v6 (Tulsa, OK, USA) were used to perform
all statistical analyses.
Sample size
Group sample sizes of 25 and 43 achieve 97% power to detect a
difference of 30.0 between the null-hypothesis, where both group
means are 30.0 and the alternative hypothesis, where the mean
of cytokine X is 60.0 with estimated group SDs of 30.0 and 30.0,
and with a significance level () of 0.05000 using a two-sided
Mann–Whitney U-test assuming that the actual distribution is
uniform.
Multivariate analysis
Hierarchical clustering using Pearson’s correlation coefficient as
the distance metric [24, 25] was used to assess cytokine similarity.
Next, the resulting ‘distance matrix’ (here representing correla-
tional strength) was sorted by cytokine to align the most
similar cytokines closer to one another. The resorted distance
matrix was then plotted like a heat map using SigmaPlot 2001
(SPSS Inc., Chicago, IL, USA). Discriminant function
analysis (DFA) was used for selection of the set of analytes that
maximally discriminate among the groups studied (¼ 0.10),
built in a step-wise manner, as described previously [18, 19].
A DFA creates a discriminate function, denoted by a root,
which is an equation consisting of a linear combination of
analytes used for the prediction of group membership. Once the
analytes are selected by DFA, a leave-one-out cross-validation
is performed to protect against over-fitting. The best cross-
validated model is then reported. The final discriminatory
TABLE 1. Clinical and laboratory characteristics of patients with psoriatic arthritis
Patient No. Age Sex Type of psoriasis Therapy No. of swollen joints No. of tender joints WBC HgB ESR CRP RF ANA
1 45 F PV MTX 2 12 5.8 12.8 8 5 0 0
2 40 M PV COX-2 MTX 0 0 6.4 16.1 10 11 0 0
3 26 F PV – 0 11 6.6 13.9 4 5 0 0
4 58 F PV COX-2 MTX 1 2 9.2 14.9 26 20 0 0
5 57 F PV COX-2 3 15 4.9 12.7 39 5 1 1
6 73 M PV NSAID 4 22 9.3 16.1 2 5 0 0
7 33 F PV COX-2 MTX 2 26 10.4 12.2 10 5 0 0
8 69 F PP NSAID 3 20 6 11.7 7 5 0 0
9 72 M PV COX-2 4 9 4.9 13.8 19 5 0 0
10 58 F PV – 2 21 4.7 13.8 21 5 0 0
11 48 M PV COX-2 MTX 4 5 15.1 15.6 20 5 0 0
12 34 M PV NSAID 0 6 6.7 16 2 5 0 0
13 57 M PV COX-2 LEF 8 29 4.8 15.4 5 5 0 0
14 61 F PV NSAID MTX 1 7 701 14.5 3 5 0 0
15 51 M PV NSAID MTX SUL 10 14 7.3 13.8 10 16 1 0
16 53 M PV COX-2 5 16 6.6 14.6 15 23 0 0
17 67 M PV NSAID 9 37 9 15.1 5 5 0 0
18 55 F PP COX-2 MTX PRED 2 5 10.7 14.9 3 5 0 0
19 50 M PV NSAID HYDCL 2 10 8.1 14.1 24 25 0 0
20 55 F PV NSAID LEF 5 27 – – – – 0 0
21 50 F PV COX-2 SUL 2 13 5.4 14 3 5 0 0
22 46 M PV COX-2 0 15 4.8 14.4 10 5 0 0
23 56 F PV NSAID 8 23 5 15 15 5 0 0
24 65 F PV COX-2 SUL 1 24 5.9 12.7 11 5 0 0
25 32 F PV COX-2 MTX TNF 1 6 7.3 13.8 13 5 0 0
26 56 M PV COX-2 1 8 6.1 16.3 1 5 0 0
27 59 M PV NSAID MTX 1 7 8.6 15.2 1 5 0 0
28 70 M PV COX-2 0 27 6.1 16.6 1 5 0 0
29 61 F PP NSAID SUL 7 8 4.6 12.4 27 16 0 0
30 44 M PV NSAID 4 4 6.3 14.9 3 5 1 0
31 74 F PV – 4 7 10.2 13.8 27 34 0 0
32 54 F PV NSAID 8 13 6.4 13.1 14 18 0 1
33 47 M PV COX-2 MTX 0 23 8.5 14.4 3 5 0 0
34 35 M PV NSAID MTX 0 0 6.7 15.3 1 5 0 0
35 45 F PV NSAID LEF 0 9 8.4 12.6 31 15 0 0
36 46 F PV NSAID MTX 7 15 4.7 12.2 32 5 0 0
37 68 F PV NSAID 1 4 9.6 14.4 20 10 0 0
38 54 F PV COX-2 2 2 10.4 14 7 5 0 0
39 56 M PV – 0 2 7.6 15.1 3 5 0 0
40 74 M PV – 0 4 3.8 14.4 10 5 0 0
41 57 F PV NSAID MTX 2 5 7.2 13.1 17 5 0 0
42 58 F PV COX-2 11 9 4.9 13.2 6 5 0 0
43 43 F PV MTX 1 7 6.5 13.3 6 5 0 0
ANA, anti-nuclear antibody (0¼negative, 1¼positive) (norm 0.00–0.99); COX-2, selective cyclo-oxigenase-2 inhibitor; CRP, C-reactive protein
(norm< 10); ESR, erythrocyte sedimentation rate (norm 0–20mm/hr); HYDCL, hydroxy-chloroquine; F, female; HgB, haemoglobin (norm: 13.2–16.6 g/
dl for men and 11.6–16.0 for women); M, male; MTX, methotrexate, NSAID, non-steroidal anti-inflammatory drugs (unselective), LEF, leflunomide;
PP, pustulosis palmoplantaris; PRED, prednisolone (2.5mg/day); PV, psoriasis vulgaris; RF, rheumatoid factor (0¼negative, 1¼positive: Waaler 128);
SUL, sulfasalazine, TNF, TNF-blocking agent (Infliximab); WBC, white blood cell count (norm 3.5–11.0 109/l).
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power of each analyte is characterized by a partial Wilk’s Lambda
coefficient; 1.0 (no discriminatory power) to 0.0 (perfect
discriminatory power). The discriminatory potential of a DFA
analysis is best realized through a simple scatter plot of the roots.
Simulation studies
A total of 500 Monte Carlo simulation studies were performed on
the hierarchal cluster analysis to estimate the strength of random
correlations. The simulations can be defined as follows:
(i) Estimate the average and SD of each analyte in each group
(normal or PsA).
(ii) Generate 43 or 25 numbers (depending on whether the
normal or PsA group is being examined) from a normal
distribution using the estimates found in 1) for each analyte.
(iii) Create a hierarchical cluster from the simulated data
(see above for details).
(iv) Repeat 1–3 500 times.
(v) Determine the 95% percentile of correlations and denote
it as .
All values greater than  have <5% chance of being caused by
random fluctuations in the data.
Results
Univariate comparison of serum cytokines in patients
with PsA and unaffected controls
Among the ‘cellular cytokines’, only IFN- (P¼ 0.039) was
significantly increased in PsA patients compared with the levels
found in healthy individuals (Fig. 1A). Among humoral cytokines,
the levels of IL-10 (P¼ 0.0107) and IL-13 (P¼ 0.0006) were
significantly elevated in patients (Fig. 1B), as were the chemokines
CCL3 (MIP-1) (P< 0.0001), CCL4 (MIP-1) (P< 0.0001) and
CCL11 (Eotaxin) (P¼ 0.0101), and the growth and angiogenic
factors EGF (P< 0.0001), VEGF (P< 0.0001), FGF (P< 0.0001)
(Fig. 1C and D). G-CSF was significantly decreased (P¼ 0.014) in
the patient group compared with controls (Fig. 1C).
Comparison of serum cytokine levels among PsA patients
with variation in disease severity
Patients were divided based on swollen joint counts. Group 1
consisted of 8 patients with counts of 0; group 2 (12 patients), 1–3,
and group 3 (12 patients), 4. Increases in the average levels IL-2,
IL-12(p40), IL-15, IFN- and CCL3 appeared elevated in patients
of group 3 relative to groups 1 and 2 (Fig. 2A–D). These results
suggest that a more active Th1/cellular immunity may be at play
in a subset of patients with a more severe disease. Accordingly,
serum levels of IL-2 appear to correlate with increasing disease
severity among the three groups (Fig. 2A–D). When the levels of
these differential analytes were evaluated using discriminant
functional analysis, IFN-, IL-15 and IL-2 were identified as
being significantly discriminatory between the three groups
with a P-value of 0.012, 0.026 and 0.069, respectively (Table 2),
suggesting the potential role of a T-cell signature in the
aetiopathogenesis of the disease.
Characterization of cohort profiles by hierarchical clustering
Hierarchical clustering was used to identify sets of cytokines
whose expression changes are linearly related within a given
population, i.e. sets of cytokines whose expression levels among
individuals within a population are correlated. In this method,
correlation coefficients between pairs of cytokines are positive for
cytokines that are consistently at the same level in individuals
of a given population under study, negative for cytokines that
FIG. 1. Comparison of various serum cytokine levels between PsA patients (n¼ 43) and controls (n¼ 25). Bars show the mean in pg/ml
and SEM. (A) Levels of circulating cellular cytokines. (B) Levels of humoral cytokines. (C) Levels of growth factors. (D) Circulating
chemokine levels. *Significantly different from compared values by Mann–Whitney U-test (P< 0.05).
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are at opposite levels (one is high, while one is low) and neutral
when there is a lack of a correlation in levels. Coregulated sets
of variables will display similar trends in variance that can be
identified and used for cluster assignment.
The results of these analyses were represented in graphical
outputs, denoted as heatmaps. In a heatmap, correlated cytokines
are grouped together. Moreover, heatmaps utilize colour mapping
of correlation coefficients to facilitate visual assessment of these
values among a large set of variables. Analytes with positive
correlations are represented in graded shades of red and negative
correlations in graded shades of blue, allowing these groups of
correlated variables to be readily identified by visual inspection as
relatively monochromatic clusters.
Several gross differences between the heatmaps from healthy
individuals and PsA patients were observed (Fig. 3A and B). The
most pronounced was a large cluster of highly correlative
cytokines identified in patients, which contained IL-2,
IL-12(p40), IL-15, TNF-, MIP-1, MIP-1, IFN- and FGF
that was not present in healthy controls. These results reflect a
disease-specific change in the regulation of these cytokine levels
in the periphery. A subset of these cytokines was identified in
the above univariate analysis as being differentially expressed.
The high correlation values of these cytokines within individual
PsA patients suggests that in addition to being ‘up-regulated’
as identified, they participate in processes that result from
coordination of their levels. Given the collection of cytokines
in this cluster, these results underscore the likely functional
relevance of Th1/cellular immunity in this disease, an immune
response bias shown to be highly relevant in the skin-aspects
of PsA [26–28].
In order to further facilitate visual characterization of the
difference in cluster patterns between patient and control cluster
heatmaps, an analysis, denoted as ‘extraction heatmap’ method,
was developed in which the heatmaps between the control and
PsA matrices were subtracted from each other and the differences
between the two visually represented (Fig. 3C).
Multiple Monte Carlo simulations were used to define the
threshold  below which significant correlations are unlikely to
appear by chance, thus providing a measure of the statistical
differences in the correlational coefficients characterized. Using
the results of these simulation studies as a reference, the most
significant changes in correlation values between patients and
controls were observed for CCL3 (MIP-1), CCL4 (MIP-1),
FGF, CCL11 (Eotaxin), IFN-, IL-2, TNF-, IL-15 and
IL-12p40, suggesting that changes in regulation of these cytokines
are highly characteristic of PsA (Fig. 3D). These results could
be used to develop a multivariate-based diagnostic test for the
disease, a test that is likely to be significantly more powerful in
terms of disease discrimination than those developed from simple
univariate studies of up- and down-regulation of peripheral
cytokines.
Identification of serum cytokine levels correlated
with disease activity
Multivariate analyses can better distinguish variables that are
characteristic of disease subsets when heterogeneous populations
are analysed than the univariate analyses utilized above. This is
in part because univariate analyses are based on identifying
differences in the averages among populations, while hierarchical
clustering distinguishes patterns on an individual basis and are
thus unaffected by heterogeneity in the overall cytokine levels
FIG. 2. Comparison of various serum cytokine levels among PsA patients with various affected joint counts. Bars show the mean
in pg/ml and SEM. (A) Levels of circulating cellular cytokines. (B) Levels of humoral cytokines. (C) Levels of growth factors.
(D) Circulating chemokine levels. *Significantly different from compared values by Mann–Whitney U-test (P< 0.05).
TABLE 2. Cytokines identified by discriminant function analysis as being
significantly discriminatory among PsA patients with various affected
joint counts
Wilk’s Lambda P-value
IFN- 0.8385 0.0121
IL-15 0.7879 0.0263
IL-2 0.7295 0.0690
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within a given subgroup. Accordingly, although differences in
single cytokine values described earlier did not reach statistical
significance, differences in the coordinated regulation of serum
cytokine levels among the three disease activity subsets described
earlier (swollen joint counts: 0, 1–3, 4) were readily observed
using hierarchical clustering (Fig. 4A–C). These differences in
cytokine patterns among disease severity subgroups can serve as
a ‘cytokine fingerprint’ for the development of prognostic
tests and also help guide an understanding of the mechanistic
differences among these groups. For example, the group 3
heatmap (swollen joint counts: 4) was most distinct from more
mild disease subgroups in that it exhibited a high positive
correlation of several pro-inflammatory cytokines (Fig. 4C vs
Fig. 4A and B, large clusters, lower left corner). These results
demonstrate that these cytokines are present in the periphery as
a unit in individuals with severe disease, and may therefore have a
cooperative function.
Discriminant function analysis (DFA)
DFA is a multivariate discrimination method that uses observed
changes in variables to characterize the most discriminatory
variables amongst groups. The diagnostic power of these
discriminatory variables is enhanced, as they are used additively
to create the class discrimination algorithms, denoted roots,
derived from this method. A ‘root’ is a linear combination of
variables with constant coefficients. DFA includes in the roots
variables that minimize group overlap in a multidimensional plot
of root values (Fig. 5). Root values for individuals within each of
the three populations analysed formed non-overlapping clusters,
suggesting that the results of the DFA can be used for developing
cytokine-based serum diagnostic criteria that could distinguish
these groups through a clinical blood test. The cytokines EGF,
IFN-, VEGF, CCL3 (MIP-1) and IL-12p40 were identified
as having the highest discriminatory activity. This is a subset
of the cytokines identified by univariate methods distinguishing
patients from controls. Also, the all but one of these cytokines
were characterized as discriminatory by hierarchical clustering,
highlighting the potential significance of these mediators in PsA.
Discussion
Inflammatory infiltrate of lymphocytes in the dermal papillae of
the skin and the stromal lining of the joints in PsA results in the
collagenase cleavage of cartilage collagen early in the disease and
is achieved through the release of various chemokines and
cytokines through cytokine-driven production of proteases [2].
The aim of this study was to describe subpopulations of
circulating cytokines likely to drive a broad spectrum of
FIG. 3. Hierarchical clustering comparing PsA patients and controls. A heatmap representation of the correlational coefficients are
graphed. Cytokines with positive correlations are represented in graded shades of red and negative correlations in graded shades of blue.
The same order of the analytes along axis is used for all the three heatmaps. (A) Controls, (B) PsA patients and (C) extraction heatmap
differences between the heatmap representations of patients and controls were isolated and depicted in an extraction heatmap.
Representation of the level of correlations is listed on the side of the graph. (D) Graphical representation of Monte Carlo simulations that
were used to define the threshold  above which significant correlations are unlikely to appear.
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autoimmune processes in patients with PsA. Besides the descrip-
tion of the differences in the circulating cytokine network between
healthy individuals and patients, we further subcategorized the
patients based on their affected joint counts as a reflection of
the disease severity. We have identified a subset of cytokines
that significantly differ between controls and PsA, as well as
differentiate between various subsets of patients with PsA.
We have characterized different cytokine profiles according to
the present disease activity, compared these disease groups and
pinpointed special subsets of cytokines that are attributed to the
particular disease subset.
The key cytokines that discriminate between PsA and healthy
individuals were IL-10, IL-13, IFN-, EGF, VEGF, FGF, CCL3
(MIP-1), CCL4 (MIP-1), CCL11 (Eotaxin) and G-CSF. These
findings support the hypothesis that a broad spectrum of impaired
immune functions are involved in the pathogenesis of PsA,
affecting cellular, humoral immune responses and various
leucocyte functions. Although a few of the cytokines related to
PsA have been described previously [9–11], the majority of these
significant cytokines have not been identified in PsA. With the
advanced multiplex cytokine array system, a novel and distinct
PsA-related serum cytokine pattern has been revealed that
discriminated between patients and healthy individuals.
Since limited system information can be obtained from
univariate analysis on the synergistic and/or antagonistic
FIG. 4. Hierarchical clustering comparing PsA patients with various affected joint counts. A heatmap representation of the correlational
coefficients are graphed. Cytokines with positive correlations are represented in graded shades of red and negative correlations in graded
shades of blue. Representations of the level of correlations are listed on the side of the graphs. (A) PsA patients with 0 affected joints,
(B) PsA patients with 1–3 affected joints and (C) PsA patients with 4 affected joints.
FIG. 5. A graphical representation of the discriminatory
potential of discriminant function analysis (DFA). The analysis
was used to select variables that maximally discriminate
among the cohort, represented by a multidimensional plot of
root values.
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multifaceted network of cytokines driving the immune/
autoimmune processes, a more complex approach utilizing
various multivariate statistical analyses was used in this study.
Hierarchical clustering was utilized to identify the changes in
cytokine networks, as this method clusters cytokines, whose
relative values are correlated on individual basis within a
population. In this analysis, CCL3 (MIP-1), CCL4 (MIP-1),
FGF, CCL11 (Eotaxin), IFN-, IL-2, TNF-, IL-15 and
IL-12p40 were found to distinguish between PsA patients and
healthy individuals. Finally, DFA pinpointed EGF, IFN-,
VEGF, CCL3 (MIP-1) and IL-12p40 to discriminate among
controls and subsets of PsA patients. The parallel evaluation of
univariate analysis, hierarchical clustering and DFA, besides
others, revealed CCL3 (MIP-1) to be the major distinctive
cytokine between PsA patients and healthy individuals. CCL3
(MIP-1) is involved in the cell activation of human granulocytes
and appears to be involved in acute neutrophilic inflammation.
Also, it stimulates the production of reactive oxygen species in
neutrophils and the release of lysosomal enzymes. Furthermore,
CCL3 (MIP-1) induces the synthesis of other pro-inflammatory
cytokines, such as IL-1, IL-6 and TNF- in fibroblasts and
macrophages [29–32]. These findings support the idea that this
chemokine can play a crucial pro-inflammatory role in the
pathogenesis of PsA and strongly associated with arthritis
development.
Further investigations, utilizing the multiplex cytokine
assay may be used to describe the in situ cytokine milieu in PsA
synovial fluid (SF)/synovium. Recently, the expression of pro-
inflammatory cytokines in the synovial biopsy of PsA patients
has been described [33]. PsA synovium was characterized by
a predominant expression of IL-10, IL-15, IFN-, IL-1, and
TNF- [33].
In the study by Partsch et al., the concentrations of T cell-
derived cytokines in the synovial fluids (SFs) of patients with PsA
in comparison with rheumatoid arthritis (RA) and osteoarthritis
(OA) was described [34]. They found that the pattern of T cell-
derived cytokines in PsA SFs was similar to that of RA SFs.
However, both the frequency and the concentrations of cytokines
were lower in PsA SFs than in RA SFs. The presence of Th1 and
Th2 cell-derived cytokines in PsA SFs suggests the presence of
activated T cells in the inflamed joint tissues and their participa-
tion in the immuno-inflammatory events [34].
The assessment of pro-inflammatory cytokines in the SF of
patients with PsA in comparison with RA and OA showed that
the levels of TNF-, IL-1, and IL-8 were significantly higher
in PsA SF than in OA SF, although lower than in RA SF [35].
The pattern of expression of pro-inflammatory cytokines seen
in PsA is similar to that in RA. Since PsA is also a destructive
arthropathy, cytokines, in particular TNF- and IL-1, may be the
principle factors in joint destruction [35].
Early immune vascular remorphology and dysregulated angio-
genesis have been hypothesized as prominent features linked
to the specific up-regulation of growth factors in PsA [2]. Our
data is consistent with this hypothesis with angiogenic growth
factors like EGF and VEGF being identified as significantly
discriminatory between patients and unaffected controls, further
reflecting the role of these players in the molecular and cellular
mechanisms responsible for the vascular remorphology and the
formation of pathological new bone in PsA.
Our results imply that a complex disorder of secreted serum
cytokine levels driving various immuno-competent cell types can
be found in PsA patients. Also, different patterns of circulating
cytokines were detected according to different disease activities
of PsA. We assume that the utilization of the multiplex cytokine
array system in PsA provides a powerful tool to sub-categorize
the disease and, along with common clinical and laboratory
parameters, help to evaluate disease activity.
In this study, we focused on static time points to describe the
cytokine profile of the patients, with similar disease activity and
have compared them with unaffected healthy controls. Serial
follow-ups of these patients may result in fluctuations in cytokine
levels that sometimes accompanies disease flare or remissions
as is evident from profiles identified in other ongoing studies (our
unpublished observations). This validates the utility of the
multiplex assay as an important application to monitor ther-
apeutic response to various treatment profiles in patients
with PsA.
A future important application of this technology will be to
evaluate the circulating cytokine pattern and thereby help sub-
categorizing patients with PsA and develop this technology to
become a powerful diagnostic tool. By the simultaneous monitor-
ing of general laboratory values and serum multiplex cytokine
levels prognostic, therapeutic assessments and monitoring can
be achieved [e.g. anti-CCL3 (MIP-1) therapy]. Recently, other
biological agents have been studied in PsA. A group of drugs is
being developed, which inhibit T cells by blocking the ‘second
signal’ of T-cell activation (e.g. alefacept, efalizumab, abatacept)
[36]. In these studies, 20–50% of the patients with PsA appeared
to be responders to these therapies [36]. Opposed to these
empirical therapies, for the first time, our results clearly identified
a subset of PsA patients with a strong T cell-mediated pathology;
therefore by utilizing correlational clustering and DFA excellent
candidates for anti-T cell therapy can be selected based on their
cytokine profiles.
Long, empirical therapies can be replaced by optimized
combination therapies through personalized pro-inflammatory
cytokine targeting and planned advanced cost–benefit strategies.
The utilization of the multiplex cytokine array system will aid in
the diagnosis and therapy design in PsA, and will provide an
advanced disease management in the future.
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